US Pricing ‘Particularly Negative’ for Swiss Unit, Says Roche

The effect of Donald Trump’s new drug pricing policy requiring drugmakers to match US prices with those elsewhere will be particularly acute on its Swiss business, Roche Holding AG Chairman Severin Schwan told NZZ.

“Such scenarios would have particularly negative consequences for our Swiss operations, where we cover many global functions in research and production,” Schwan told the paper. “A large portion of our added value and local jobs is financed by our business in the USA. We pay more in taxes in Switzerland than we generate in revenue.”

Pharmaceutical companies are raising prices elsewhere instead of bringing them ...